IXC 0.00% 6.6¢ invex therapeutics ltd

Ann: Publication of Invex IIH Phase II Pressure Trial Results, page-5

  1. 993 Posts.
    lightbulb Created with Sketch. 848
    Great read, here are my favourite parts referring to a secondary indication;

    https://hotcopper.com.au/data/attachments/5122/5122083-8a6ae26bb12420b143e097b3fef12399.jpg
    and
    https://hotcopper.com.au/data/attachments/5122/5122101-ea218ca52706e26ed13f74238565b7e6.jpg
    and
    https://hotcopper.com.au/data/attachments/5122/5122118-a3e9988659e239ef4e7d12960950ecd5.jpg

    This pairs well with the development strategy section of the IXC website;

    https://hotcopper.com.au/data/attachments/5122/5122126-2ddf41e0fe10f28da2e360a235ca0b0a.jpg

    To speculate, I think we see a secondary indication announced for preliminary trial workstreams later this year. smile.png


 
watchlist Created with Sketch. Add IXC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.